CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
Kyoungmin Lee, Kyunghye Bang, Changhoon Yoo, Inhwan Hwang, Jae Ho Jeong, Heung-Moon Chang, Dongwook Oh, Tae Jun Song, Do Hyun Park, Sang Soo Lee, Sung Koo Lee, Myung-Hwan Kim, Jin-hong Park, Kyu-pyo Kim, Baek-Yeol Ryoo
Cancer Research and Treatment. 2020;52(1):254-262.   Published online 2019 July 9    DOI: https://doi.org/10.4143/crt.2019.190

Excel Download

Clinical outcomes of second-line chemotherapy after progression on nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma
Annals of Oncology. 2019;30:ix55   Crossref logo
Link1 Link2 Link3 Link4

Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
Cancer Research and Treatment. 2020;52(1):254-262   Crossref logo
Link1 Link2 Link3

Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
Journal of Cancer Research and Clinical Oncology. 2020;147(5):1529-1536   Crossref logo
Link1 Link2 Link3

Su1157 EFFICACY OF MODIFIED FOLFIRINOX AS SECOND-LINE CHEMOTHERAPY IN METASTATIC PANCREATIC ADENOCARCINOMA AFTER GEMCITABINE PLUS NAB-PACLITAXEL FAILURE
Gastroenterology. 2020;158(6):S-527   Crossref logo
Link1 Link2

Baseline characteristics and second-line treatment for metastatic pancreatic adenocarcinoma (mPAC) patients receiving first-line FOLFIRINOX, gemcitabine+nab-paclitaxel or gemcitabine-monotherapy in routine clinical practice across Europe
Annals of Oncology. 2018;29:v93   Crossref logo
Link1 Link2 Link3

Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma

Cancer Management and Research. 2020;Volume 12:12657-12666   Crossref logo
Link1 Link2

Observational study of comparative effectiveness of nab-paclitaxel plus gemcitabine vs gemcitabine plus cisplatin or gemcitabine alone for the first-line treatment of metastatic pancreatic adenocarcinoma in the University Hospital Centre Zagreb
Annals of Oncology. 2018;29:v46   Crossref logo
Link1 Link2 Link3

Efficacy of S-1 in 2L chemotherapy after nab-paclitaxel plus gemcitabine for patients with advanced pancreatic cancer
Annals of Oncology. 2019;30:vi130   Crossref logo
Link1 Link2 Link3 Link4

The emerging role of third-line gemcitabine plus nab-paclitaxel in advanced pancreatic adenocarcinoma
Annals of Oncology. 2019;30:ix61-ix62   Crossref logo
Link1 Link2 Link3 Link4

FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer

Cancer Management and Research. 2020;Volume 12:10271-10278   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.